Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms

HORSHAM, PA (April 3, 2000) -- Exisulind (Aptosyn™) and other selective apoptotic antineoplastic drugs (SAANDs) inhibit the growth of prostate cancer cells in two ways, said researchers from Columbia University and their collaborators at Cell Pathways, Inc. (Nasdaq: CLPA). First, they directly kill cancerous prostate cells by inducing apoptosis. Secondly, they decrease expression of the androgen receptor in the cancerous prostate cells, making them less responsive to the growth-promoting effects of androgens in their environment. The Columbia University scientists and their Cell Pathways' collaborators presented their preclinical findings on Sunday April 2, 2000 at the annual meeting of the American Association for Cancer Research (AACR) in San Francisco.

The researchers also demonstrated in a prostate cancer cell line that exisulind (Aptosyn™) and two other SAANDs, CP461 and CP248, inhibited the cellular expression and secretion of prostate specific antigen (PSA) at the same concentrations that induced apoptosis in the cells.

Dr. Bernard Weinstein, the senior investigator of these studies and director of the Columbia University Comprehensive Cancer Center, emphasized that "because of their dual mechanism of action, these agents are also effective in prostate cancer cells that have become independent of androgens."

"These findings also support the usefulness of PSA assays for measuring the efficacy of SAANDs in clinical trials for prostate cancer therapy or chemoprevention, as they demonstrate that a reduction in PSA levels accurately reflects cell death and not merely a reduction in PSA production when these drugs are used," added Rifat Pamukcu, M.D., chief scientific officer and senior vice president of research at Cell Pathways, Inc.

"This laboratory research complements the findings of our clinical trial of exisulind (Aptosyn™) as a treatment for post-prostatectomy men at risk of prostate cancer recurre

Contact: Joan Kureczka
Kureczka/Martin Associates

Page: 1 2 3

Related biology news :

1. New molecular link key to cellular proteins involved in cancer progression, other diseases
2. New hydrothermal vents discovered as South Pacific Odyssey research begins
3. Posters highlight water, energy and other natural resource research
4. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes
5. K-State, other universities to study how climate affects plant evolution
6. The search for a kinder, gentler chemotherapy
7. Green tea research leads to gum and other products
8. New survey reveals insights into unique relationship between mothers and pediatricians
9. Manatee population rising in some regions, likely stalled or declining in others
10. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
11. Another key for the p53 door

Post Your Comments:

(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/1/2016)... -- Favorable Government Initiatives Coupled With Implementation ... to Boost Global Biometrics System Market Through 2021  ... " Global Biometrics Market By Type, By End ... - 2021", the global biometrics market is projected to ... growing security concerns across various end use sectors such ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. Hays ... DNA as a Field Application Specialist. , “I am thrilled that Dr. Young ... DNA. “In further expanding our capacity as a scientific integrator, Hays brings a wealth ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
(Date:6/23/2016)... June 22, 2016  Amgen (NASDAQ: AMGN ... QB3@953 life sciences incubator to accelerate the ... shared laboratory space at QB3@953 was created to help ... obstacle for many early stage organizations - access to ... sponsorship, Amgen launched two "Amgen Golden Ticket" awards, providing ...
Breaking Biology Technology:
Cached News: